2-Methyl-heptamethylenimin | 116557-53-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Methyl-heptamethylenimin
• 英文别名: 2-methyl-azocane；2-methyl-octahydro-azocine；2-Methyl-octahydro-azocin；2-Methyl-octahydroazocine；2-methylazocane
• CAS: 116557-53-0
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: MHEHELVTSIPICT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  8-amino-octan-2-one 在 乙醇 、 sodium 作用下， 生成 2-Methyl-heptamethylenimin
  参考文献：
  名称：

  Gabriel, Chemische Berichte, 1910, vol. 43, p. 358

  摘要：

  DOI：

文献信息

• [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
  申请人：SANKYO CO

  公开号：WO2003106435A1

  公开（公告）日：2003-12-24

  AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

  新化合物具有以下式（I）的结构，其药学上可接受的盐和酯可以调节LXR功能，从而表现出优秀的抗动脉粥样硬化和抗炎活性：其中：A代表芳基或杂环芳基；R1、R2和R3相同或不同，每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-（烷基羰基）-N-（烷基）氨基、烷氧羰基氨基、N-（烷氧羰基）-N-（烷基）氨基、烷磺酰氨基、N-（烷磺酰基）-N-（烷基）氨基、卤代烷基磺酰氨基、N-（卤代烷基磺酰基）-N-（烷基）氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基，或R1和R2一起是亚烷二氧基；R4和R5相同或不同，每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基；X代表氢、羟基、卤素、烷氧基或卤代烷氧基；Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
• PYRAZOLE DERIVATIVE MANUFACTURING METHOD
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20170217958A1

  公开（公告）日：2017-08-03

  The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method. [C217]

  本发明提供了一种制造由化学式(I)表示的化合物的方法。利用这种方法，提供了一种制造4-杂环芳基-N-(2-苯基-[1,2,4]三唑并[1,5-a]吡啶-7-基)-1H-吡唑-5-羧酸酰胺衍生物的方法；以及用于这种制造方法的中间体。
• Detection and Treatment of Schizophrenia
  申请人：Itokawa Masanari

  公开号：US20110028470A1

  公开（公告）日：2011-02-03

  The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.

  本发明提供了一种用于诊断精神分裂症的方法，以及用于该方法的精神分裂症诊断试剂或设备。本发明进一步提供了一种治疗或改善精神分裂症的药剂，该药剂对于治疗或改善精神分裂症有效。用于治疗或改善精神分裂症的药剂包含醛固定剂或醛修饰蛋白形成抑制剂作为活性成分。根据本发明的诊断精神分裂症的方法包括在受试者中测量至少一个参数，所述参数选自以下组合：（1）甘氧化酶I基因的遗传异常；（2）生物样本中甘氧化酶I的表达水平或活性；（3）蛋白质中醛化合物或经醛化合物修饰的蛋白质的量；以及（4）生物样本中吡哆醛的量。
• DETECTION AND TREATMENT OF SCHIZOPHRENIA
  申请人：TOKAI UNIVERSITY EDUCATIONAL SYSTEM

  公开号：EP2189537A1

  公开（公告）日：2010-05-26

  The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.

  本发明提供了一种诊断精神分裂症的方法，以及一种用于该方法的精神分裂症诊断试剂或装置。本发明进一步提供了一种治疗或改善精神分裂症的药剂，该药剂可有效治疗或改善精神分裂症。精神分裂症的治疗剂或改善剂含有羰基清除剂或羰基修饰蛋白形成抑制剂作为活性成分。根据本发明的诊断精神分裂症的方法包括测量受试者体内的至少一个参数，该参数选自由以下组成的组：(1)乙二醛酶I基因的遗传异常；(2)生物样本中乙二醛酶I的表达水平或活性；(3)羰基化合物或羰基修饰蛋白的量，该蛋白是用羰基化合物修饰的蛋白；(4)生物样本中吡哆醛的量。
• Detection and treatment of schizophrenia
  申请人：TOKAI UNIVERSITY EDUCATIONAL SYSTEM

  公开号：EP2662453A2

  公开（公告）日：2013-11-13

  The present invention relates to a method for diagnosing schizophrenia comprising measuring at least one parameter in a subject, the parameter being selected from the group consisting of (1) a genetic abnormality of glyoxalase I gene, (2) the expression level or activity of glyoxalase I in a biological sample, (3) the amount of a carbonyl-modified protein that is a protein modified with the carbonyl-compound, preferably pentosidine, in a biological sample, and (4) the amount of pyridoxal in a biological sample. The present further relates to a primer, a probe and a reagent for use in said method, as well as an AGE-reader and its use for measuring the amount of carbonyl-modified proteins.

  本发明涉及一种诊断精神分裂症的方法，该方法包括测量受试者体内的至少一个参数，该参数选自以下组别：(1)乙二醛酶 I 基因的遗传异常；(2)生物样本中乙二醛酶 I 的表达水平或活性；(3)生物样本中羰基修饰蛋白质的量，该蛋白质是用羰基化合物（最好是喷托西啶）修饰的蛋白质；(4)生物样本中吡哆醛的量。本发明还涉及一种用于上述方法的引物、探针和试剂，以及一种 AGE 读取器及其在测量羰基修饰蛋白质量时的用途。